Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAC1 | P63000 | 3/20 | 0.82 |
| ▸ | RAC2 | P15153 | 1/20 | 0.82 |
| ▸ | RAC3 | P60763 | 1/20 | 0.82 |
| ▸ | APLNR | P35414 | 2/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1461351 | 0.90 | RAC1 (1.00) | RAC1RAC2RAC3APLNR | |
| SCHEMBL30798860 | 0.90 | RAC1 (1.00) | RAC1RAC2RAC3APLNR | |
| Hydrochloric Acid SCHEMBL384979 | 0.90 | RAC1 (1.00) | RAC1RAC2RAC3APLNR | |
| Hydrochloric Acid SCHEMBL29383079 | 0.90 | RAC1 (1.00) | RAC1RAC2RAC3APLNR | |
| SCHEMBL20677994 | 0.87 | RAC1 (0.73) | RAC1RAC2RAC3APLNR | |
| SCHEMBL1460422 | 0.86 | RAC1 (0.87) | RAC1RAC2RAC3APLNRADRB2 | |
| SCHEMBL20683278 | 0.86 | RAC1 (0.71) | RAC1RAC2RAC3APLNR | |
| SCHEMBL20678077 | 0.86 | RAC1 (0.71) | RAC1RAC2RAC3APLNR | |
| SCHEMBL4499457 | 0.85 | RAC1 (0.84) | RAC1RAC2RAC3APLNRADRB2 | |
| SCHEMBL1461829 | 0.85 | RAC1 (0.84) | RAC1RAC2RAC3APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472352-B2 | Rac inhibitors | Geneyus LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472352-B2 | Rac inhibitors | Geneyus LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190031647-A1 | RAC INHIBITORS | Geneyus LLC (US) | 2019-01-31 | — | — | US | disclosed |
| US-20190031647-A1 | RAC INHIBITORS | Geneyus LLC (US) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031647-A1 | RAC INHIBITORS | ARHGDIB, ARHGDIA, RAC1 | RAC1 3/4885RAC2 4/4885RAC3 10/4885 |
| US-10472352-B2 | Rac inhibitors | ARHGDIB, ARHGDIA, RAC1 | RAC1 3/4885RAC2 4/4885RAC3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.